Abstract
Recently, we found that different low molecular weight compounds, all known to stabilize proteins in their native conformation, are effective in correcting the temperature-sensitive protein folding defect associated with the ΔF508 cystic fibrosis transmembrane regulator (CFTR) protein. Here we examined whether the folding of other proteins which exhibit temperature- sensitive folding defects also could be corrected via a similar strategy. Cell lines expressing temperature-sensitive mutants of the tumor suppressor protein p53, the viral oncogene protein pp60(src), or a ubiquitin activating enzyme E1, were incubated at the nonpermissive temperature (39.5°C) in the presence of glycerol, trimethylamine N-oxide or deuterated water. In each case, the cells exhibited phenotypes similar to those observed when the cells were incubated at the permissive temperature (32.5°C), indicative that the particular protein folding defect had been corrected. These observations, coupled with our earlier work and much older studies in yeast and bacteria, indicate that protein stabilizing agents are effective in vivo for correcting protein folding abnormalities. We suggest that this type of approach may prove to be useful for correcting certain protein folding abnormalities associated with human diseases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1432-1444 |
| Number of pages | 13 |
| Journal | Journal of Clinical Investigation |
| Volume | 99 |
| Issue number | 6 |
| DOIs | |
| State | Published - Mar 15 1997 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
}
Correcting temperature-sensitive protein folding defects. / Brown, C. Randell; Hong, Ly; Welch, William J.
In: Journal of Clinical Investigation, Vol. 99, No. 6, 15.03.1997, p. 1432-1444.Research output: Contribution to journal › Article
TY - JOUR
T1 - Correcting temperature-sensitive protein folding defects
AU - Brown, C. Randell
AU - Hong, Ly
AU - Welch, William J.
PY - 1997/3/15
Y1 - 1997/3/15
N2 - Recently, we found that different low molecular weight compounds, all known to stabilize proteins in their native conformation, are effective in correcting the temperature-sensitive protein folding defect associated with the ΔF508 cystic fibrosis transmembrane regulator (CFTR) protein. Here we examined whether the folding of other proteins which exhibit temperature- sensitive folding defects also could be corrected via a similar strategy. Cell lines expressing temperature-sensitive mutants of the tumor suppressor protein p53, the viral oncogene protein pp60(src), or a ubiquitin activating enzyme E1, were incubated at the nonpermissive temperature (39.5°C) in the presence of glycerol, trimethylamine N-oxide or deuterated water. In each case, the cells exhibited phenotypes similar to those observed when the cells were incubated at the permissive temperature (32.5°C), indicative that the particular protein folding defect had been corrected. These observations, coupled with our earlier work and much older studies in yeast and bacteria, indicate that protein stabilizing agents are effective in vivo for correcting protein folding abnormalities. We suggest that this type of approach may prove to be useful for correcting certain protein folding abnormalities associated with human diseases.
AB - Recently, we found that different low molecular weight compounds, all known to stabilize proteins in their native conformation, are effective in correcting the temperature-sensitive protein folding defect associated with the ΔF508 cystic fibrosis transmembrane regulator (CFTR) protein. Here we examined whether the folding of other proteins which exhibit temperature- sensitive folding defects also could be corrected via a similar strategy. Cell lines expressing temperature-sensitive mutants of the tumor suppressor protein p53, the viral oncogene protein pp60(src), or a ubiquitin activating enzyme E1, were incubated at the nonpermissive temperature (39.5°C) in the presence of glycerol, trimethylamine N-oxide or deuterated water. In each case, the cells exhibited phenotypes similar to those observed when the cells were incubated at the permissive temperature (32.5°C), indicative that the particular protein folding defect had been corrected. These observations, coupled with our earlier work and much older studies in yeast and bacteria, indicate that protein stabilizing agents are effective in vivo for correcting protein folding abnormalities. We suggest that this type of approach may prove to be useful for correcting certain protein folding abnormalities associated with human diseases.
UR - http://www.scopus.com/inward/record.url?scp=0030896451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030896451&partnerID=8YFLogxK
U2 - 10.1172/JCI119302
DO - 10.1172/JCI119302
M3 - Article
VL - 99
SP - 1432
EP - 1444
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
SN - 0021-9738
IS - 6
ER -